Insider Buying: Longeveron Inc. (NASDAQ:LGVN) Insider Purchases 106,383 Shares of Stock

Longeveron Inc. (NASDAQ:LGVN) insider Joshua Hare bought 106,383 shares of the business’s stock in a transaction dated Wednesday, April 10th. The shares were bought at an average cost of $2.35 per share, for a total transaction of $250,000.05. Following the purchase, the insider now directly owns 590,727 shares in the company, valued at approximately $1,388,208.45. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Longeveron Trading Down 16.3 %

Shares of LGVN traded down $0.33 during trading hours on Friday, reaching $1.69. 494,120 shares of the company traded hands, compared to its average volume of 820,154. Longeveron Inc. has a 12 month low of $1.62 and a 12 month high of $44.00. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.21. The company’s fifty day moving average price is $4.32 and its two-hundred day moving average price is $12.41. The company has a market capitalization of $4.24 million, a price-to-earnings ratio of -0.17 and a beta of 0.21.

Longeveron (NASDAQ:LGVN) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($2.50) EPS for the quarter, missing the consensus estimate of ($2.10) by ($0.40). Longeveron had a negative return on equity of 209.14% and a negative net margin of 3,020.17%. The business had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.21 million. Equities research analysts predict that Longeveron Inc. will post -8.5 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Longeveron

Several hedge funds have recently bought and sold shares of LGVN. Citadel Advisors LLC bought a new stake in Longeveron during the fourth quarter worth about $44,000. Northern Trust Corp bought a new stake in Longeveron during the second quarter worth about $63,000. State Street Corp bought a new stake in Longeveron during the second quarter worth about $88,000. Geode Capital Management LLC boosted its stake in Longeveron by 78.6% during the second quarter. Geode Capital Management LLC now owns 66,392 shares of the company’s stock worth $224,000 after acquiring an additional 29,212 shares in the last quarter. Finally, Boothbay Fund Management LLC bought a new stake in Longeveron during the second quarter worth about $254,000. Institutional investors own 10.01% of the company’s stock.

About Longeveron

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young, healthy adult donors.